MDS Nordion Signs New Contract with Lantheus Medical Imaging, Inc. for the Supply of Molybdenum-99
July 08 2010 - 8:00AM
PR Newswire (Canada)
OTTAWA, July 8 /CNW/ -- OTTAWA, July 8 /CNW/ - MDS Nordion, a
leading provider of products and services to the global health
science market, today announced it has signed a new contract with
its primary customer, Lantheus Medical Imaging, Inc. for the supply
of Molybdenum-99 (Mo-99). Mo-99, and, more specifically the
derivative medial isotope Technetium-99m, is utilized in
approximately 80 percent of nuclear medical procedures worldwide.
These noninvasive procedures are essential for accurately
diagnosing and treating patients with conditions such as heart
disease, cancer and neurological conditions. "The continuous supply
of medical isotopes to meet the needs of the global medical
community and the patients it serves has always been an important
priority for Nordion. This contract with Lantheus further enables
us to maintain that commitment," said Steve West, Chief Executive
Officer, MDS Inc. "Our depth of expertise in the industry,
world-class logistical team and proven capability in the production
of medical isotopes, provides Lantheus with a solid supply chain."
Under the terms of the new agreement MDS Nordion will supply Mo-99
on a weekly basis to Lantheus Medical Imaging, Inc. This contract
is in place until July 31, 2011 and will commence once Atomic
Energy of Canada Limited's (AECL) National Research Universal (NRU)
reactor has returned to service which is anticipated to be the end
of July, 2010. "Lantheus and MDS Nordion have a long history of
working together and this contract further demonstrates our
commitment to provide medical isotopes to the global nuclear
medicine community," said Don Kiepert, President and Chief
Executive Officer, Lantheus Medical Imaging, Inc. "MDS Nordion
provides the capacity and scalability Lantheus requires so that
doctors and their patients receive critical diagnostic scans and
treatments when they need them." About MDS Inc. MDS Inc. (TSX: MDS;
NYSE: MDZ) is a global health science company that provides
market-leading products and services used for the prevention,
diagnosis and treatment of disease. We are a leading provider of
innovative technologies for use in medical imaging and
radiotherapeutics, and sterilization technologies benefiting the
lives of millions of people in more than 65 countries around the
world. Our products and services are used daily by pharmaceutical
and biotechnology companies, medical-device manufacturers,
hospitals, clinics and research laboratories. MDS has more than 700
highly skilled people in five locations. Find out more at
www.mdsnordion.com. MEDIA: Shelley Maclean, (613) 592-3400, ext.
2414, shelley.maclean@mdsinc.com; INVESTORS: Ana Raman, (613)
595-4580, investor.relations@mdsinc.com
Copyright
Mds (NYSE:MDZ)
Historical Stock Chart
From Jun 2024 to Jul 2024
Mds (NYSE:MDZ)
Historical Stock Chart
From Jul 2023 to Jul 2024